[조사자료] 글로벌 노인 황반 변성 (AMD) 치료제 시장 (2023-2032) : 애플리버셉트, 라니비주맙, 기타

■ 영문 제목 : Age Related Macular Degeneration (AMD) Market By Drug Type (Aflibercept, Ranibizumab, Others), By Disease Type (Wet Age Related Macular Degeneration (AMD), Dry Age Related Macular Degeneration (AMD)), By Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy): Global Opportunity Analysis and Industry Forecast, 2023-2032
	■ 상품코드 : ALD23SEP135 ■ 조사/발행회사 : Allied Market Research ■ 발행일 : 2023년 5월 ■ 페이지수 : 251 ■ 작성언어 : 영어 ■ 보고서 형태 : PDF ■ 납품 방식 : E메일 ■ 조사대상 지역 : 세계

■ 판매가격 / 옵션 (부가세 10% 별도)

Single User	USD5,730 ⇒환산￦7,735,500	견적의뢰/주문/질문
5 User	USD6,450 ⇒환산￦8,707,500	견적의뢰/주문/질문
Enterprise User	USD9,600 ⇒환산￦12,960,000	견적의뢰/구입/질문

※가격옵션 설명
- 납기는 즉일~2일소요됩니다. 3일이상 소요되는 경우는 별도표기 또는 연락드립니다.
- 지불방법은 계좌이체/무통장입금 또는 카드결제입니다.

글로벌 노인 황반 변성 (AMD) 치료제 시장 규모는 2022년에 94억 달러였으며 2023년부터 2032년까지 연평균 5%씩 성장하여 2032년에는 154억 달러에 달할 것으로 예상됩니다. 노인 황반 변성 (AMD)은 전 세계 수백만 명의 사람들, 특히 50세 이상의 사람들에게 영향을 미치는 흔한 눈 질환입니다. 선명한 중심 시력을 담당하는 망막의 중심부인 황반에 영향을 미치는 진행성 질환입니다. 노인 황반 변성 (AMD)의 두 가지 주요 유형은 건성 및 습성 노인 황반 변성 (AMD) 입니다. 건성 노인 황반 변성 (AMD) 은 가장 흔한 유형의 연령 관련 황반변성으로, 황반의 빛에 민감한 세포가 시간이 지남에 따라 파괴되고 죽으면서 중심 시력을 서서히 상실하게 됩니다. 습성 연령 관련 황반변성은 덜 흔하지만 더 심각한 형태의 노인 황반 변성 (AMD) 으로, 망막 아래에서 비정상적인 혈관이 자라나 체액, 혈액, 단백질이 누출되어 황반에 흉터와 손상을 일으킬 때 발생합니다.
노인 황반 변성 (AMD) 치료제 시장의 성장을 이끄는 주요 요인은 노인 인구의 증가, 효과적인 치료 옵션에 대한 수요 급증, 기술 발전입니다. 예를 들어, 세계보건기구의 2022년 팩트 시트에 따르면 2030년에는 전 세계 인구 6명 중 1명이 60세 이상이 될 것으로 예상됩니다. 2050년에는 전 세계 60세 이상 인구가 21억 명이 될 것으로 예상됩니다. 80세 이상 인구는 2050년까지 4억 2,600만 명에 달할 것으로 예상됩니다. 또한 전 세계적으로 건성 노인 황반 변성 (AMD) 치료를 위한 연령 관련 황반변성 약물에 대한 수요가 증가하면서 시장 성장이 더욱 촉진되고 있습니다.
그러나 연령 관련 황반변성 약물과 관련된 높은 비용은 향후 시장 성장을 저해 할 것으로 예상됩니다. 반대로, 노인 황반 변성 (AMD) 치료에 대한 R&D 활동의 증가와 최신 제품 승인은 가까운 장래에 시장 성장을 위한 수익성 있는 기회를 제공할 것으로 예상됩니다.

노인 황반 변성 (AMD) 치료제 시장은 약물 유형, 질병 유형, 유통 채널 및 지역으로 세분화됩니다. 약물 유형에 따라 시장은 아플리버셉트, 라니비주맙 및 기타로 분류됩니다. 질병 유형에 따라 시장은 건성 연령 관련 황반 변성 (AMD)과 습성 연령 관련 황반 변성 (AMD)으로 나뉩니다. 유통 채널을 기준으로 시장은 병원 약국, 소매 약국 및 온라인 약국으로 세분화됩니다. 지역을 기준으로 시장은 북미(미국, 캐나다, 멕시코), 유럽(독일, 프랑스, 영국, 이탈리아, 스페인, 기타 유럽 지역), 아시아 태평양(일본, 중국, 호주, 인도, 한국, 기타 아시아 태평양), 중남미/중동/아프리카(브라질, 남아프리카공화국, 사우디아라비아, 기타 중남미/중동/아프리카) 등으로 분석됩니다.
글로벌 노인 황반 변성 (AMD) 치료제 시장에서 활동하는 주요 주요 업체는 Regeneron Pharmaceuticals Inc., Novartis AG, F. Hoffmann-La Roche Ltd, Biogen, Bayer AG, Bausch Health Companies Inc, Coherus Biosciences Inc, Sanofi, Apellis Pharmaceuticals and Ionis Pharmaceuticals, Inc. 등입니다.

이해관계자를 위한 주요 이점
이 보고서는 2022년부터 2032년까지 노인 황반 변성 (AMD) 치료제 시장 분석의 시장 부문, 현재 동향, 추정치 및 역학에 대한 정량적 분석을 제공하여 일반적인 노인 황반 변성 (AMD) 치료제 시장 기회를 식별합니다.
시장 조사는 주요 동인, 제약 및 기회와 관련된 정보와 함께 제공됩니다.
포터의 다섯 가지 경쟁 요인 분석은 이해 관계자가 이익 지향적인 비즈니스 결정을 내리고 공급 업체-구매자 네트워크를 강화할 수 있도록 구매자와 공급 업체의 힘을 강조합니다.
노인 황반 변성 (AMD) 치료제시장 세분화에 대한 심층 분석은 일반적인 시장 기회를 결정하는 데 도움이 됩니다.
각 지역의 주요 국가는 글로벌 시장에 대한 매출 기여도에 따라 매핑됩니다.
시장 플레이어 포지셔닝은 벤치마킹을 용이하게하고 시장 플레이어의 현재 위치에 대한 명확한 이해를 제공합니다.
이 보고서에는 지역 및 글로벌 노인 황반 변성 (AMD) 치료제 시장 동향, 주요 업체, 시장 부문, 응용 분야 및 시장 성장 전략에 대한 분석이 포함되어 있습니다.

주요 시장 부문
약물 유형별
아플리버셉트
라니비주맙
기타

질병 유형별
습성 노인 황반 변성 (AMD) 치료제
건성 노인 황반 변성 (AMD) 치료제

유통 채널별
병원 약국
소매 약국
온라인 약국

지역별
북미
미국
캐나다
멕시코
유럽
프랑스
독일
이탈리아
스페인
영국
기타 유럽 지역
아시아 태평양
중국
일본
호주
인도
한국
기타 아시아 태평양 지역
중남미/중동/아프리카
브라질
사우디 아라비아
남아프리카 공화국
기타 중동 및 아프리카 지역

주요 기업
○ F. Hoffmann-La Roche Ltd.
○ Coherus Biosciences Inc
○ Biogen
○ Regeneron Pharmaceuticals Inc.
○ Ionis Pharmaceuticals, Inc.
○ Novartis AG
○ Bayer AG
○ Bausch Health Companies Inc.
○ Apellis Pharmaceuticals Inc.
○ Sanofi S.A.

■ 보고서 개요

CHAPTER 1 : 소개
CHAPTER 2 : 개요
CHAPTER 3 : 시장 동향
CHAPTER 4 : 노인 황반 변성 (AMD) 치료제 시장, 약물 유형별
CHAPTER 5 : 노인 황반 변성 (AMD) 치료제 시장, 질병 유형별
CHAPTER 6 : 노인 황반 변성 (AMD) 치료제 시장, 유통 채널별
CHAPTER 7 : 노인 황반 변성 (AMD) 치료제 시장, 지역별
CHAPTER 8 : 경쟁 현황
CHAPTER 9 : 기업 정보

■ 보고서 목차

CHAPTER 1: INTRODUCTION
1.1. Report description
1.2. Key market segments
1.3. Key benefits to the stakeholders
1.4. Research Methodology
1.4.1. Primary research
1.4.2. Secondary research
1.4.3. Analyst tools and models
CHAPTER 2: EXECUTIVE SUMMARY
2.1. CXO Perspective
CHAPTER 3: MARKET OVERVIEW
3.1. Market definition and scope
3.2. Key findings
3.2.1. Top impacting factors
3.2.2. Top investment pockets
3.3. Porter’s five forces analysis
3.3.1. Bargaining power of suppliers
3.3.2. Bargaining power of buyers
3.3.3. Threat of substitutes
3.3.4. Threat of new entrants
3.3.5. Intensity of rivalry
3.4. Market dynamics
3.4.1. Drivers
3.4.1.1. Increase in geriatric population
3.4.1.2. Increase in incidences of age-related macular degeneration (AMD) across the globe

3.4.2. Restraints
3.4.2.1. High cost of treatment

3.4.3. Opportunities
3.4.3.1. Increase in number of pipelines drug

3.5. COVID-19 Impact Analysis on the market
CHAPTER 4: AGE RELATED MACULAR DEGENERATION (AMD) MARKET, BY DRUG TYPE
4.1. Overview
4.1.1. Market size and forecast
4.2. Aflibercept
4.2.1. Key market trends, growth factors and opportunities
4.2.2. Market size and forecast, by region
4.2.3. Market share analysis by country
4.3. Ranibizumab
4.3.1. Key market trends, growth factors and opportunities
4.3.2. Market size and forecast, by region
4.3.3. Market share analysis by country
4.4. Others
4.4.1. Key market trends, growth factors and opportunities
4.4.2. Market size and forecast, by region
4.4.3. Market share analysis by country
CHAPTER 5: AGE RELATED MACULAR DEGENERATION (AMD) MARKET, BY DISEASE TYPE
5.1. Overview
5.1.1. Market size and forecast
5.2. Wet Age Related Macular Degeneration (AMD)
5.2.1. Key market trends, growth factors and opportunities
5.2.2. Market size and forecast, by region
5.2.3. Market share analysis by country
5.3. Dry Age Related Macular Degeneration (AMD)
5.3.1. Key market trends, growth factors and opportunities
5.3.2. Market size and forecast, by region
5.3.3. Market share analysis by country
CHAPTER 6: AGE RELATED MACULAR DEGENERATION (AMD) MARKET, BY DISTRIBUTION CHANNEL
6.1. Overview
6.1.1. Market size and forecast
6.2. Hospital Pharmacy
6.2.1. Key market trends, growth factors and opportunities
6.2.2. Market size and forecast, by region
6.2.3. Market share analysis by country
6.3. Retail Pharmacy
6.3.1. Key market trends, growth factors and opportunities
6.3.2. Market size and forecast, by region
6.3.3. Market share analysis by country
6.4. Online Pharmacy
6.4.1. Key market trends, growth factors and opportunities
6.4.2. Market size and forecast, by region
6.4.3. Market share analysis by country
CHAPTER 7: AGE RELATED MACULAR DEGENERATION (AMD) MARKET, BY REGION
7.1. Overview
7.1.1. Market size and forecast By Region
7.2. North America
7.2.1. Key trends and opportunities
7.2.2. Market size and forecast, by Drug Type
7.2.3. Market size and forecast, by Disease Type
7.2.4. Market size and forecast, by Distribution Channel
7.2.5. Market size and forecast, by country
7.2.5.1. U.S.
7.2.5.1.1. Key market trends, growth factors and opportunities
7.2.5.1.2. Market size and forecast, by Drug Type
7.2.5.1.3. Market size and forecast, by Disease Type
7.2.5.1.4. Market size and forecast, by Distribution Channel
7.2.5.2. Canada
7.2.5.2.1. Key market trends, growth factors and opportunities
7.2.5.2.2. Market size and forecast, by Drug Type
7.2.5.2.3. Market size and forecast, by Disease Type
7.2.5.2.4. Market size and forecast, by Distribution Channel
7.2.5.3. Mexico
7.2.5.3.1. Key market trends, growth factors and opportunities
7.2.5.3.2. Market size and forecast, by Drug Type
7.2.5.3.3. Market size and forecast, by Disease Type
7.2.5.3.4. Market size and forecast, by Distribution Channel
7.3. Europe
7.3.1. Key trends and opportunities
7.3.2. Market size and forecast, by Drug Type
7.3.3. Market size and forecast, by Disease Type
7.3.4. Market size and forecast, by Distribution Channel
7.3.5. Market size and forecast, by country
7.3.5.1. France
7.3.5.1.1. Key market trends, growth factors and opportunities
7.3.5.1.2. Market size and forecast, by Drug Type
7.3.5.1.3. Market size and forecast, by Disease Type
7.3.5.1.4. Market size and forecast, by Distribution Channel
7.3.5.2. Germany
7.3.5.2.1. Key market trends, growth factors and opportunities
7.3.5.2.2. Market size and forecast, by Drug Type
7.3.5.2.3. Market size and forecast, by Disease Type
7.3.5.2.4. Market size and forecast, by Distribution Channel
7.3.5.3. Italy
7.3.5.3.1. Key market trends, growth factors and opportunities
7.3.5.3.2. Market size and forecast, by Drug Type
7.3.5.3.3. Market size and forecast, by Disease Type
7.3.5.3.4. Market size and forecast, by Distribution Channel
7.3.5.4. Spain
7.3.5.4.1. Key market trends, growth factors and opportunities
7.3.5.4.2. Market size and forecast, by Drug Type
7.3.5.4.3. Market size and forecast, by Disease Type
7.3.5.4.4. Market size and forecast, by Distribution Channel
7.3.5.5. UK
7.3.5.5.1. Key market trends, growth factors and opportunities
7.3.5.5.2. Market size and forecast, by Drug Type
7.3.5.5.3. Market size and forecast, by Disease Type
7.3.5.5.4. Market size and forecast, by Distribution Channel
7.3.5.6. Rest of Europe
7.3.5.6.1. Key market trends, growth factors and opportunities
7.3.5.6.2. Market size and forecast, by Drug Type
7.3.5.6.3. Market size and forecast, by Disease Type
7.3.5.6.4. Market size and forecast, by Distribution Channel
7.4. Asia-Pacific
7.4.1. Key trends and opportunities
7.4.2. Market size and forecast, by Drug Type
7.4.3. Market size and forecast, by Disease Type
7.4.4. Market size and forecast, by Distribution Channel
7.4.5. Market size and forecast, by country
7.4.5.1. China
7.4.5.1.1. Key market trends, growth factors and opportunities
7.4.5.1.2. Market size and forecast, by Drug Type
7.4.5.1.3. Market size and forecast, by Disease Type
7.4.5.1.4. Market size and forecast, by Distribution Channel
7.4.5.2. Japan
7.4.5.2.1. Key market trends, growth factors and opportunities
7.4.5.2.2. Market size and forecast, by Drug Type
7.4.5.2.3. Market size and forecast, by Disease Type
7.4.5.2.4. Market size and forecast, by Distribution Channel
7.4.5.3. Australia
7.4.5.3.1. Key market trends, growth factors and opportunities
7.4.5.3.2. Market size and forecast, by Drug Type
7.4.5.3.3. Market size and forecast, by Disease Type
7.4.5.3.4. Market size and forecast, by Distribution Channel
7.4.5.4. India
7.4.5.4.1. Key market trends, growth factors and opportunities
7.4.5.4.2. Market size and forecast, by Drug Type
7.4.5.4.3. Market size and forecast, by Disease Type
7.4.5.4.4. Market size and forecast, by Distribution Channel
7.4.5.5. South Korea
7.4.5.5.1. Key market trends, growth factors and opportunities
7.4.5.5.2. Market size and forecast, by Drug Type
7.4.5.5.3. Market size and forecast, by Disease Type
7.4.5.5.4. Market size and forecast, by Distribution Channel
7.4.5.6. Rest of Asia-Pacific
7.4.5.6.1. Key market trends, growth factors and opportunities
7.4.5.6.2. Market size and forecast, by Drug Type
7.4.5.6.3. Market size and forecast, by Disease Type
7.4.5.6.4. Market size and forecast, by Distribution Channel
7.5. LAMEA
7.5.1. Key trends and opportunities
7.5.2. Market size and forecast, by Drug Type
7.5.3. Market size and forecast, by Disease Type
7.5.4. Market size and forecast, by Distribution Channel
7.5.5. Market size and forecast, by country
7.5.5.1. Brazil
7.5.5.1.1. Key market trends, growth factors and opportunities
7.5.5.1.2. Market size and forecast, by Drug Type
7.5.5.1.3. Market size and forecast, by Disease Type
7.5.5.1.4. Market size and forecast, by Distribution Channel
7.5.5.2. Saudi Arabia
7.5.5.2.1. Key market trends, growth factors and opportunities
7.5.5.2.2. Market size and forecast, by Drug Type
7.5.5.2.3. Market size and forecast, by Disease Type
7.5.5.2.4. Market size and forecast, by Distribution Channel
7.5.5.3. South Africa
7.5.5.3.1. Key market trends, growth factors and opportunities
7.5.5.3.2. Market size and forecast, by Drug Type
7.5.5.3.3. Market size and forecast, by Disease Type
7.5.5.3.4. Market size and forecast, by Distribution Channel
7.5.5.4. Rest of LAMEA
7.5.5.4.1. Key market trends, growth factors and opportunities
7.5.5.4.2. Market size and forecast, by Drug Type
7.5.5.4.3. Market size and forecast, by Disease Type
7.5.5.4.4. Market size and forecast, by Distribution Channel
CHAPTER 8: COMPETITIVE LANDSCAPE
8.1. Introduction
8.2. Top winning strategies
8.3. Product Mapping of Top 10 Player
8.4. Competitive Dashboard
8.5. Competitive Heatmap
8.6. Top player positioning, 2022
CHAPTER 9: COMPANY PROFILES
9.1. Regeneron Pharmaceuticals Inc.
9.1.1. Company overview
9.1.2. Key Executives
9.1.3. Company snapshot
9.1.4. Operating business segments
9.1.5. Product portfolio
9.1.6. Business performance
9.2. Novartis AG
9.2.1. Company overview
9.2.2. Key Executives
9.2.3. Company snapshot
9.2.4. Operating business segments
9.2.5. Product portfolio
9.2.6. Business performance
9.2.7. Key strategic moves and developments
9.3. F. Hoffmann-La Roche Ltd.
9.3.1. Company overview
9.3.2. Key Executives
9.3.3. Company snapshot
9.3.4. Operating business segments
9.3.5. Product portfolio
9.3.6. Business performance
9.3.7. Key strategic moves and developments
9.4. Biogen
9.4.1. Company overview
9.4.2. Key Executives
9.4.3. Company snapshot
9.4.4. Operating business segments
9.4.5. Product portfolio
9.4.6. Business performance
9.4.7. Key strategic moves and developments
9.5. Bayer AG
9.5.1. Company overview
9.5.2. Key Executives
9.5.3. Company snapshot
9.5.4. Operating business segments
9.5.5. Product portfolio
9.5.6. Business performance
9.6. Coherus Biosciences Inc
9.6.1. Company overview
9.6.2. Key Executives
9.6.3. Company snapshot
9.6.4. Operating business segments
9.6.5. Product portfolio
9.6.6. Business performance
9.6.7. Key strategic moves and developments
9.7. Sanofi S.A.
9.7.1. Company overview
9.7.2. Key Executives
9.7.3. Company snapshot
9.7.4. Operating business segments
9.7.5. Product portfolio
9.7.6. Business performance
9.8. Apellis Pharmaceuticals Inc.
9.8.1. Company overview
9.8.2. Key Executives
9.8.3. Company snapshot
9.8.4. Operating business segments
9.8.5. Product portfolio
9.8.6. Business performance
9.8.7. Key strategic moves and developments
9.9. Bausch Health Companies Inc.
9.9.1. Company overview
9.9.2. Key Executives
9.9.3. Company snapshot
9.9.4. Operating business segments
9.9.5. Product portfolio
9.9.6. Business performance
9.10. Ionis Pharmaceuticals, Inc.
9.10.1. Company overview
9.10.2. Key Executives
9.10.3. Company snapshot
9.10.4. Operating business segments
9.10.5. Product portfolio
9.10.6. Business performance

LIST OF TABLES
TABLE 01. GLOBAL AGE RELATED MACULAR DEGENERATION (AMD) MARKET, BY DRUG TYPE, 2022-2032 ($MILLION)
TABLE 02. AGE RELATED MACULAR DEGENERATION (AMD) MARKET FOR AFLIBERCEPT, BY REGION, 2022-2032 ($MILLION)
TABLE 03. AGE RELATED MACULAR DEGENERATION (AMD) MARKET FOR RANIBIZUMAB, BY REGION, 2022-2032 ($MILLION)
TABLE 04. AGE RELATED MACULAR DEGENERATION (AMD) MARKET FOR OTHERS, BY REGION, 2022-2032 ($MILLION)
TABLE 05. GLOBAL AGE RELATED MACULAR DEGENERATION (AMD) MARKET, BY DISEASE TYPE, 2022-2032 ($MILLION)
TABLE 06. AGE RELATED MACULAR DEGENERATION (AMD) MARKET FOR WET AGE RELATED MACULAR DEGENERATION (AMD), BY REGION, 2022-2032 ($MILLION)
TABLE 07. AGE RELATED MACULAR DEGENERATION (AMD) MARKET FOR DRY AGE RELATED MACULAR DEGENERATION (AMD), BY REGION, 2022-2032 ($MILLION)
TABLE 08. GLOBAL AGE RELATED MACULAR DEGENERATION (AMD) MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
TABLE 09. AGE RELATED MACULAR DEGENERATION (AMD) MARKET FOR HOSPITAL PHARMACY, BY REGION, 2022-2032 ($MILLION)
TABLE 10. AGE RELATED MACULAR DEGENERATION (AMD) MARKET FOR RETAIL PHARMACY, BY REGION, 2022-2032 ($MILLION)
TABLE 11. AGE RELATED MACULAR DEGENERATION (AMD) MARKET FOR ONLINE PHARMACY, BY REGION, 2022-2032 ($MILLION)
TABLE 12. AGE RELATED MACULAR DEGENERATION (AMD) MARKET, BY REGION, 2022-2032 ($MILLION)
TABLE 13. NORTH AMERICA AGE RELATED MACULAR DEGENERATION (AMD) MARKET, BY DRUG TYPE, 2022-2032 ($MILLION)
TABLE 14. NORTH AMERICA AGE RELATED MACULAR DEGENERATION (AMD) MARKET, BY DISEASE TYPE, 2022-2032 ($MILLION)
TABLE 15. NORTH AMERICA AGE RELATED MACULAR DEGENERATION (AMD) MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
TABLE 16. NORTH AMERICA AGE RELATED MACULAR DEGENERATION (AMD) MARKET, BY COUNTRY, 2022-2032 ($MILLION)
TABLE 17. U.S. AGE RELATED MACULAR DEGENERATION (AMD) MARKET, BY DRUG TYPE, 2022-2032 ($MILLION)
TABLE 18. U.S. AGE RELATED MACULAR DEGENERATION (AMD) MARKET, BY DISEASE TYPE, 2022-2032 ($MILLION)
TABLE 19. U.S. AGE RELATED MACULAR DEGENERATION (AMD) MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
TABLE 20. CANADA AGE RELATED MACULAR DEGENERATION (AMD) MARKET, BY DRUG TYPE, 2022-2032 ($MILLION)
TABLE 21. CANADA AGE RELATED MACULAR DEGENERATION (AMD) MARKET, BY DISEASE TYPE, 2022-2032 ($MILLION)
TABLE 22. CANADA AGE RELATED MACULAR DEGENERATION (AMD) MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
TABLE 23. MEXICO AGE RELATED MACULAR DEGENERATION (AMD) MARKET, BY DRUG TYPE, 2022-2032 ($MILLION)
TABLE 24. MEXICO AGE RELATED MACULAR DEGENERATION (AMD) MARKET, BY DISEASE TYPE, 2022-2032 ($MILLION)
TABLE 25. MEXICO AGE RELATED MACULAR DEGENERATION (AMD) MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
TABLE 26. EUROPE AGE RELATED MACULAR DEGENERATION (AMD) MARKET, BY DRUG TYPE, 2022-2032 ($MILLION)
TABLE 27. EUROPE AGE RELATED MACULAR DEGENERATION (AMD) MARKET, BY DISEASE TYPE, 2022-2032 ($MILLION)
TABLE 28. EUROPE AGE RELATED MACULAR DEGENERATION (AMD) MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
TABLE 29. EUROPE AGE RELATED MACULAR DEGENERATION (AMD) MARKET, BY COUNTRY, 2022-2032 ($MILLION)
TABLE 30. FRANCE AGE RELATED MACULAR DEGENERATION (AMD) MARKET, BY DRUG TYPE, 2022-2032 ($MILLION)
TABLE 31. FRANCE AGE RELATED MACULAR DEGENERATION (AMD) MARKET, BY DISEASE TYPE, 2022-2032 ($MILLION)
TABLE 32. FRANCE AGE RELATED MACULAR DEGENERATION (AMD) MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
TABLE 33. GERMANY AGE RELATED MACULAR DEGENERATION (AMD) MARKET, BY DRUG TYPE, 2022-2032 ($MILLION)
TABLE 34. GERMANY AGE RELATED MACULAR DEGENERATION (AMD) MARKET, BY DISEASE TYPE, 2022-2032 ($MILLION)
TABLE 35. GERMANY AGE RELATED MACULAR DEGENERATION (AMD) MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
TABLE 36. ITALY AGE RELATED MACULAR DEGENERATION (AMD) MARKET, BY DRUG TYPE, 2022-2032 ($MILLION)
TABLE 37. ITALY AGE RELATED MACULAR DEGENERATION (AMD) MARKET, BY DISEASE TYPE, 2022-2032 ($MILLION)
TABLE 38. ITALY AGE RELATED MACULAR DEGENERATION (AMD) MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
TABLE 39. SPAIN AGE RELATED MACULAR DEGENERATION (AMD) MARKET, BY DRUG TYPE, 2022-2032 ($MILLION)
TABLE 40. SPAIN AGE RELATED MACULAR DEGENERATION (AMD) MARKET, BY DISEASE TYPE, 2022-2032 ($MILLION)
TABLE 41. SPAIN AGE RELATED MACULAR DEGENERATION (AMD) MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
TABLE 42. UK AGE RELATED MACULAR DEGENERATION (AMD) MARKET, BY DRUG TYPE, 2022-2032 ($MILLION)
TABLE 43. UK AGE RELATED MACULAR DEGENERATION (AMD) MARKET, BY DISEASE TYPE, 2022-2032 ($MILLION)
TABLE 44. UK AGE RELATED MACULAR DEGENERATION (AMD) MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
TABLE 45. REST OF EUROPE AGE RELATED MACULAR DEGENERATION (AMD) MARKET, BY DRUG TYPE, 2022-2032 ($MILLION)
TABLE 46. REST OF EUROPE AGE RELATED MACULAR DEGENERATION (AMD) MARKET, BY DISEASE TYPE, 2022-2032 ($MILLION)
TABLE 47. REST OF EUROPE AGE RELATED MACULAR DEGENERATION (AMD) MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
TABLE 48. ASIA-PACIFIC AGE RELATED MACULAR DEGENERATION (AMD) MARKET, BY DRUG TYPE, 2022-2032 ($MILLION)
TABLE 49. ASIA-PACIFIC AGE RELATED MACULAR DEGENERATION (AMD) MARKET, BY DISEASE TYPE, 2022-2032 ($MILLION)
TABLE 50. ASIA-PACIFIC AGE RELATED MACULAR DEGENERATION (AMD) MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
TABLE 51. ASIA-PACIFIC AGE RELATED MACULAR DEGENERATION (AMD) MARKET, BY COUNTRY, 2022-2032 ($MILLION)
TABLE 52. CHINA AGE RELATED MACULAR DEGENERATION (AMD) MARKET, BY DRUG TYPE, 2022-2032 ($MILLION)
TABLE 53. CHINA AGE RELATED MACULAR DEGENERATION (AMD) MARKET, BY DISEASE TYPE, 2022-2032 ($MILLION)
TABLE 54. CHINA AGE RELATED MACULAR DEGENERATION (AMD) MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
TABLE 55. JAPAN AGE RELATED MACULAR DEGENERATION (AMD) MARKET, BY DRUG TYPE, 2022-2032 ($MILLION)
TABLE 56. JAPAN AGE RELATED MACULAR DEGENERATION (AMD) MARKET, BY DISEASE TYPE, 2022-2032 ($MILLION)
TABLE 57. JAPAN AGE RELATED MACULAR DEGENERATION (AMD) MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
TABLE 58. AUSTRALIA AGE RELATED MACULAR DEGENERATION (AMD) MARKET, BY DRUG TYPE, 2022-2032 ($MILLION)
TABLE 59. AUSTRALIA AGE RELATED MACULAR DEGENERATION (AMD) MARKET, BY DISEASE TYPE, 2022-2032 ($MILLION)
TABLE 60. AUSTRALIA AGE RELATED MACULAR DEGENERATION (AMD) MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
TABLE 61. INDIA AGE RELATED MACULAR DEGENERATION (AMD) MARKET, BY DRUG TYPE, 2022-2032 ($MILLION)
TABLE 62. INDIA AGE RELATED MACULAR DEGENERATION (AMD) MARKET, BY DISEASE TYPE, 2022-2032 ($MILLION)
TABLE 63. INDIA AGE RELATED MACULAR DEGENERATION (AMD) MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
TABLE 64. SOUTH KOREA AGE RELATED MACULAR DEGENERATION (AMD) MARKET, BY DRUG TYPE, 2022-2032 ($MILLION)
TABLE 65. SOUTH KOREA AGE RELATED MACULAR DEGENERATION (AMD) MARKET, BY DISEASE TYPE, 2022-2032 ($MILLION)
TABLE 66. SOUTH KOREA AGE RELATED MACULAR DEGENERATION (AMD) MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
TABLE 67. REST OF ASIA-PACIFIC AGE RELATED MACULAR DEGENERATION (AMD) MARKET, BY DRUG TYPE, 2022-2032 ($MILLION)
TABLE 68. REST OF ASIA-PACIFIC AGE RELATED MACULAR DEGENERATION (AMD) MARKET, BY DISEASE TYPE, 2022-2032 ($MILLION)
TABLE 69. REST OF ASIA-PACIFIC AGE RELATED MACULAR DEGENERATION (AMD) MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
TABLE 70. LAMEA AGE RELATED MACULAR DEGENERATION (AMD) MARKET, BY DRUG TYPE, 2022-2032 ($MILLION)
TABLE 71. LAMEA AGE RELATED MACULAR DEGENERATION (AMD) MARKET, BY DISEASE TYPE, 2022-2032 ($MILLION)
TABLE 72. LAMEA AGE RELATED MACULAR DEGENERATION (AMD) MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
TABLE 73. LAMEA AGE RELATED MACULAR DEGENERATION (AMD) MARKET, BY COUNTRY, 2022-2032 ($MILLION)
TABLE 74. BRAZIL AGE RELATED MACULAR DEGENERATION (AMD) MARKET, BY DRUG TYPE, 2022-2032 ($MILLION)
TABLE 75. BRAZIL AGE RELATED MACULAR DEGENERATION (AMD) MARKET, BY DISEASE TYPE, 2022-2032 ($MILLION)
TABLE 76. BRAZIL AGE RELATED MACULAR DEGENERATION (AMD) MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
TABLE 77. SAUDI ARABIA AGE RELATED MACULAR DEGENERATION (AMD) MARKET, BY DRUG TYPE, 2022-2032 ($MILLION)
TABLE 78. SAUDI ARABIA AGE RELATED MACULAR DEGENERATION (AMD) MARKET, BY DISEASE TYPE, 2022-2032 ($MILLION)
TABLE 79. SAUDI ARABIA AGE RELATED MACULAR DEGENERATION (AMD) MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
TABLE 80. SOUTH AFRICA AGE RELATED MACULAR DEGENERATION (AMD) MARKET, BY DRUG TYPE, 2022-2032 ($MILLION)
TABLE 81. SOUTH AFRICA AGE RELATED MACULAR DEGENERATION (AMD) MARKET, BY DISEASE TYPE, 2022-2032 ($MILLION)
TABLE 82. SOUTH AFRICA AGE RELATED MACULAR DEGENERATION (AMD) MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
TABLE 83. REST OF LAMEA AGE RELATED MACULAR DEGENERATION (AMD) MARKET, BY DRUG TYPE, 2022-2032 ($MILLION)
TABLE 84. REST OF LAMEA AGE RELATED MACULAR DEGENERATION (AMD) MARKET, BY DISEASE TYPE, 2022-2032 ($MILLION)
TABLE 85. REST OF LAMEA AGE RELATED MACULAR DEGENERATION (AMD) MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
TABLE 86. REGENERON PHARMACEUTICALS INC.: KEY EXECUTIVES
TABLE 87. REGENERON PHARMACEUTICALS INC.: COMPANY SNAPSHOT
TABLE 88. REGENERON PHARMACEUTICALS INC.: PRODUCT SEGMENTS
TABLE 89. REGENERON PHARMACEUTICALS INC.: PRODUCT PORTFOLIO
TABLE 90. NOVARTIS AG: KEY EXECUTIVES
TABLE 91. NOVARTIS AG: COMPANY SNAPSHOT
TABLE 92. NOVARTIS AG: PRODUCT SEGMENTS
TABLE 93. NOVARTIS AG: PRODUCT PORTFOLIO
TABLE 94. NOVARTIS AG: KEY STRATERGIES
TABLE 95. F. HOFFMANN-LA ROCHE LTD.: KEY EXECUTIVES
TABLE 96. F. HOFFMANN-LA ROCHE LTD.: COMPANY SNAPSHOT
TABLE 97. F. HOFFMANN-LA ROCHE LTD.: PRODUCT SEGMENTS
TABLE 98. F. HOFFMANN-LA ROCHE LTD.: PRODUCT PORTFOLIO
TABLE 99. F. HOFFMANN-LA ROCHE LTD.: KEY STRATERGIES
TABLE 100. BIOGEN: KEY EXECUTIVES
TABLE 101. BIOGEN: COMPANY SNAPSHOT
TABLE 102. BIOGEN: PRODUCT SEGMENTS
TABLE 103. BIOGEN: PRODUCT PORTFOLIO
TABLE 104. BIOGEN: KEY STRATERGIES
TABLE 105. BAYER AG: KEY EXECUTIVES
TABLE 106. BAYER AG: COMPANY SNAPSHOT
TABLE 107. BAYER AG: PRODUCT SEGMENTS
TABLE 108. BAYER AG: PRODUCT PORTFOLIO
TABLE 109. COHERUS BIOSCIENCES INC: KEY EXECUTIVES
TABLE 110. COHERUS BIOSCIENCES INC: COMPANY SNAPSHOT
TABLE 111. COHERUS BIOSCIENCES INC: PRODUCT SEGMENTS
TABLE 112. COHERUS BIOSCIENCES INC: PRODUCT PORTFOLIO
TABLE 113. COHERUS BIOSCIENCES INC: KEY STRATERGIES
TABLE 114. SANOFI S.A.: KEY EXECUTIVES
TABLE 115. SANOFI S.A.: COMPANY SNAPSHOT
TABLE 116. SANOFI S.A.: PRODUCT SEGMENTS
TABLE 117. SANOFI S.A.: PRODUCT PORTFOLIO
TABLE 118. APELLIS PHARMACEUTICALS INC.: KEY EXECUTIVES
TABLE 119. APELLIS PHARMACEUTICALS INC.: COMPANY SNAPSHOT
TABLE 120. APELLIS PHARMACEUTICALS INC.: PRODUCT SEGMENTS
TABLE 121. APELLIS PHARMACEUTICALS INC.: PRODUCT PORTFOLIO
TABLE 122. APELLIS PHARMACEUTICALS INC.: KEY STRATERGIES
TABLE 123. BAUSCH HEALTH COMPANIES INC.: KEY EXECUTIVES
TABLE 124. BAUSCH HEALTH COMPANIES INC.: COMPANY SNAPSHOT
TABLE 125. BAUSCH HEALTH COMPANIES INC.: PRODUCT SEGMENTS
TABLE 126. BAUSCH HEALTH COMPANIES INC.: PRODUCT PORTFOLIO
TABLE 127. IONIS PHARMACEUTICALS, INC.: KEY EXECUTIVES
TABLE 128. IONIS PHARMACEUTICALS, INC.: COMPANY SNAPSHOT
TABLE 129. IONIS PHARMACEUTICALS, INC.: PRODUCT SEGMENTS
TABLE 130. IONIS PHARMACEUTICALS, INC.: PRODUCT PORTFOLIO

※본 조사보고서 [글로벌 노인 황반 변성 (AMD) 치료제 시장 (2023-2032) : 애플리버셉트, 라니비주맙, 기타] (코드 : ALD23SEP135) 판매에 관한 면책사항을 반드시 확인하세요.

※본 조사보고서 [글로벌 노인 황반 변성 (AMD) 치료제 시장 (2023-2032) : 애플리버셉트, 라니비주맙, 기타] 에 대해서 E메일 문의는 여기를 클릭하세요.

※당 사이트에 없는 보고서도 취급 가능한 경우가 많으니 문의 주세요!

[이하, 관련 보고서 소개]

글로벌 출혈성 질환 시장 (2023-2032) : 혈우병 A, 혈우병 B, 폰빌레브란트병, 기타
ALD23SEP133 / Allied Market Research / 2023년 5월 / 글로벌 출혈성 질환 시장은 2022년에 137억 8,966만 달러로 평가되었으며 2032년에는 259억 7,482만 달러에 달할 것으로 예상되며, 2023년부터 2032년까지 6.6%의 연평균 성장률을 보일 것으로 예상됩니다. 출혈성 질환는 혈액 내 특정 응고...CHAPTER 1 : 소개 CHAPTER 2 : 개요 CHAPTER 3 : 시장 동향 CHAPTER 4 : 출혈성 질환 시장, 질병 유형별 CHAPTER 5 : 출혈성 질환 시장, 치료 유형별 CHAPTER 6 : 출혈성 질환 시장, 유통 채널별 CHAPTER 7 : 출혈성 질환 시장, 지역별 CHAPTER 8 : 경쟁 현황 CHAPTER...

글로벌 승모판막 질환 치료제 시장 (2023-2032) : 베타 차단제, 이뇨제, 항응고제, 기타
ALD23SEP151 / Allied Market Research / 2023년 5월 / 글로벌 승모판막 질환 치료제 시장은 2022년 6억 7,774만 달러에 달했으며 2023년부터 2032년까지 2.8%의 연평균 성장률을 보이며 2032년에는 8억 3,344만 달러에 달할 것으로 예상됩니다. 승모판막 질환은 심장의 좌심방과 좌심실 사이에 위치한...CHAPTER 1 : 소개 CHAPTER 2 : 개요 CHAPTER 3 : 시장 동향 CHAPTER 4 : 승모판막 질환 치료제 시장, 약품 종류별 CHAPTER 5 : 승모판막 질환 치료제 시장, 연령대별 CHAPTER 6 : 승모판막 질환 치료제 시장, 유통 채널별 CHAPTER 7 : 승모판막 질환 치료제 시장, 지역별 CHAPTER 8 :...

글로벌 원발성 담즙성 담관염 (PBC) 치료제 시장 (2023-2032) : 1차 약물, 2차 약물
ALD23SEP174 / Allied Market Research / 2023년 6월 / 글로벌 원발성 담즙성 담관염 (PBC) 치료제 시장은 2022년에 6억 8,395만 달러로 평가되었으며 2023년부터 2032년까지 7.1%의 연평균 성장률을 보이며 2032년에는 13억 6,000만 달러에 달할 것으로 예상됩니다. 원발성 담즙성 담관염(PBC) 치료제는 질환을...CHAPTER 1 : 소개 CHAPTER 2 : 개요 CHAPTER 3 : 시장 동향 CHAPTER 4 : 원발성 담즙성 담관염(PBC) 치료제 시장, 약제 유형별 CHAPTER 5 : 원발성 담즙성 담관염(PBC) 치료제 시장, 유통채널별 CHAPTER 6 : 원발성 담즙성 담관염(PBC) 치료제 시장, 지역별 CHAPTER 7 : 경쟁 현황 CHAPTER 8 : 기업...

글로벌 림프종 치료제 시장 (2023-2032) : 호지킨 림프종, 비호지킨 림프종
ALD23SEP105 / Allied Market Research / 2023년 4월 / 세계의 림프종 치료제 시장은 2022년 156억 9,145만 달러로 평가되며 2023년부터 2032년까지 8.4%의 연평균 성장률을 보이며 2032년에는 352억 7,450만 달러에 달할 것으로 예상됩니다. 림프종은 감염 및 기타 질병과 싸우는 데 도움이...CHAPTER 1 : 소개 CHAPTER 2 : 개요 CHAPTER 3 : 시장 동향 CHAPTER 4 : 림프종 치료제 시장, 질병 유형별 CHAPTER 5 : 림프종 치료제 시장, 치료 유형별 CHAPTER 6 : 림프종 치료제 시장, 투여 경로별 CHAPTER 7 : 림프종 치료제 시장, 유통 채널별 CHAPTER 8 : 림프종 치료제...

글로벌 죽상동맥경화증 치료제 시장 (2023-2032) : 항혈소판제 및 항응고제, 콜레스테롤 저하제, ACE 억제제, 기타
ALD23SEP122 / Allied Market Research / 2023년 4월 / 글로벌 죽상동맥경화증 치료제 시장은 2022년 20,608.51백만 달러에 달했으며 2032년에는 27,711.92백만 달러에 달할 것으로 예상되며, 2023년부터 2032년까지 3%의 연평균 성장률을 보일 것으로 전망됩니다. 죽상동맥경화증은 플라크가 쌓여 동맥 벽이 딱딱해져 정맥이 좁아지는...CHAPTER 1 : 소개 CHAPTER 2 : 개요 CHAPTER 3 : 시장 동향 CHAPTER 4 : 죽상동맥경화증 치료제 시장, 약제 유형별 CHAPTER 5 : 죽상동맥경화증 치료제 시장, 투여 경로별 CHAPTER 6 : 죽상동맥경화증 치료제 시장, 유통채널별 CHAPTER 7 : 죽상동맥경화증 치료제 시장, 지역별 CHAPTER 8 : 경쟁 현황 CHAPTER 9...